Medical policy
Ocrevus® (Ocrelizumab) and Ocrevus Zunovo™ (Ocrelizumab and Hyaluronidase-Ocsq)…
United Healthcare medical policy 2022D0056J · Oct 1, 2025
Key facts
| Policy title | Ocrevus® (Ocrelizumab) and Ocrevus Zunovo™ (Ocrelizumab and Hyaluronidase-Ocsq) - Commercial Medical Benefit Drug Policy |
|---|---|
| Insurer | United Healthcare |
| Policy number | 2022D0056J |
| Policy date | Oct 1, 2025 |
| Current policy | Yes |
| ICD-10 codes | G35 |
| Insurer page | uhcprovider.com |
At a glance
- None 510(k)s referenced
- None PMAs referenced
- None De Novos referenced
- 1–9 Clinical trials referenced
- 1–9 Articles referenced
- None UDI devices referenced
- None NDC products referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Insurer medical policies
Insurer clinical and medical policies state when a payer covers a device, drug or procedure. Orca1 links each policy to the FDA submissions, trials and articles it cites. Policy text is not reproduced here.
Source: Health insurer clinical and medical policies (insurer as listed); cross-links by Orca1